http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8119127-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bf5765d0fee47c8bdf0788cc5b38b98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd4d3284d1de21406a22ef53993a2b19 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate | 2005-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49288c72bfb47ca51e3b748771777562 |
| publicationDate | 2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-8119127-B2 |
| titleOfInvention | Cytokine antagonists for neurological and neuropsychiatric disorders |
| abstract | Methods for treating neurological or neuropsychiatric diseases or disorders in humans by administering to the human a therapeutically effective dose of specific biologics are presented. The biologics of consideration include antagonists of tumor necrosis factor or of interleukin-1. The administration of these biologics is performed by specific methods, most, but not all of which fall into the category of anatomically localized administration designed for perispinal use. Anatomically localized administration involving perispinal use includes, but is not limited to the subcutaneous, intramuscular, interspinous, epidural, peridural, parenteral or intrathecal routes. Additionally, intranasal administration is discussed as a method to provide therapeutic benefit. n The clinical conditions of consideration include, but are not limited to the following: diseases of the brain, including neurodegenerative diseases such as Alzheimer's Disease and Parkinson's Disease; migraine headache; spinal radiculopathy associated with intervertebral disc herniation, post-herpetic neuralgia, reflex sympathetic dystrophy, neuropathic pain, vertebral disc disease, low back pain, amyotrophic lateral sclerosis, chronic fatigue syndrome; and neuropsychiatric diseases, including bipolar affective disorder, anorexia nervosa, nicotine withdrawal, narcotic addiction, alcohol withdrawal, post-partum depression, and schizoaffective illness. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9886546-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010093829-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010047235-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10325068-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010040609-A1 |
| priorityDate | 1999-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.